NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
RANEXA (ranolazine) by Menarini is cytochrome p450 3a inhibitors [moa]. Approved for coronary artery disease, angina pectoris, myocardial ischemia. First approved in 2006.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RANEXA (ranolazine) is an oral extended-release small molecule that inhibits cytochrome P450 3A, used primarily to treat coronary artery disease and chronic angina pectoris. It works by modulating cellular metabolism to improve myocardial efficiency and reduce ischemia-induced symptoms. The drug has expanded indications across cardiovascular and metabolic conditions including heart failure, atrial fibrillation, and type 2 diabetes.
$2MPart D
LOE ApproachingDeclining
With LOE approaching and minimal Part D spending ($2M), the RANEXA brand team is in managed decline mode with likely skeleton crew focus on retention and transition planning.
Mechanism of Action
Cytochrome P450 3A Inhibitors
Worked on RANEXA at Menarini? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.